Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF-mutant advanced melanoma: A matching-adjusted indirect comparison.
- DOI
- 10.1136/bmjonc-2025-000912
- Published
- 2025
- Container
- BMJ oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/bmjonc-2025-000912,
title = {Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF-mutant advanced melanoma: A matching-adjusted indirect comparison.},
author = {Miller DM and Smithy JW and Palaia J and Patel D and Salvatore A and D'Adamo D and Mattera M and Zhou ZY and Garcia-Horton V and Tarhini AA},
year = {2025},
journal = {BMJ oncology},
doi = {10.1136/bmjonc-2025-000912},
url = {https://doi.org/10.1136/bmjonc-2025-000912}
}RIS
TY - JOUR TI - Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF-mutant advanced melanoma: A matching-adjusted indirect comparison. AU - Miller DM AU - Smithy JW AU - Palaia J AU - Patel D AU - Salvatore A AU - D'Adamo D AU - Mattera M AU - Zhou ZY AU - Garcia-Horton V AU - Tarhini AA PY - 2025 JO - BMJ oncology DO - 10.1136/bmjonc-2025-000912 UR - https://doi.org/10.1136/bmjonc-2025-000912 ER -
APA
DM, M., JW, S., J, P., D, P., A, S., D, D., M, M., ZY, Z., V, G., & AA, T. (2025). Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF-mutant advanced melanoma: A matching-adjusted indirect comparison.. BMJ oncology. https://doi.org/10.1136/bmjonc-2025-000912
Source records
- pubmed · retrieved 2026-09-27T10:05:57.039Z
- europe-pmc · retrieved 2026-09-27T10:05:57.043Z
- doaj · retrieved 2026-09-27T10:05:57.056Z